吉非替尼治疗晚期肺腺癌的疗效和毒副作用
Factors Contributed to Anticancer and Adverse Effects in Advanced Adenocarcinoma of Lung with Iressa
-
摘要: 目的 评价吉非替尼(Gefitinib)治疗晚期肺腺癌的疗效及毒副反应。 方法 对55例化疗失败或不宜化疗的Ⅳ期肺腺癌患者给予吉非替尼口服250mg/d,至病情进展或出现不可耐受的不良反应。 结果 55例患者中无CR患者，PR 21例(38.2%),SD水相逢15例(27.3%),疾病控制率(DCR=CR+PR + SD)65.5%,PD19例(34.5%)。中位肿瘤进展时间(TTP)为7.2月,1年生存率为43.6%。与药物相关的不良反应依次为痤疮样皮疹28 例(50.9%),皮肤干燥19例(34.5%),腹泻14例（25.5%), 恶心7例(12.7%)，肝功能异常(ALT,AST 升高)1例(1.8%)。 结论 吉非替尼治疗晚期肺腺癌有效,毒副反应轻微,患者依从性和耐受性好Abstract: Objective To evaluate the efficacy and toxicity of Gefitinib in the treatment of advanced adenocarcinoma of lung. Methods Fifty five patients with stage Ⅳadenocarcinoma of the lung who had failed or not tolerated or refused chemotherapy received 250mg oral doses of Gefitinib once a day，until disease progression or development to intolerable toxic reaction. Results There was no complete regression observed,partial response(PR) rate was 38.2%(21/55),stable disease (SD) 27.3% (15/55),disease control rate (CR+PR+SD)65.5%, progression of disease(PD) 34.5% (19/55) and median time to tumor progression(TTP) was 7.2 month. One year survival rate was 43.6%.The drug-related adverse reactions were skin rash 28(50.9%),dry skin 19(34.5%),diarrhea 14(25.5%),nausea 7(12.7%),and hepatic dysfunction (ALT and AST increase) 1 (1.8%). Conclusion Gefitinib is active in patients with advanced adenocarcinoma of lung. It is well tolerated with minimal side effects. All patients have well compliance and tolerability.
下载:
